Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm Receives Strategic Investment for up to A$18 mill

Thursday, June 20, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has secured a strategic investment of up to A$18 million to bolster its clinical programs. This funding is expected to enhance the development of its therapeutic candidates, particularly in ongoing clinical studies. The company has also reported positive updates across its various programs, indicating strong progress in its research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm received a significant strategic investment of up to A$18 million.
  • The funding will support ongoing clinical studies and development programs.
  • Positive clinical updates have been reported across multiple programs.

Full Press Release Details

• Announcements
• Price Sensitive
• June 20, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• March 15, 2025
• Announcements
• December 9, 2022
• Announcements
• January 24, 2024
• Announcements
• March 3, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount of the investment Radiopharm received?

Radiopharm received a strategic investment of up to A$18 million.

What will the investment support?

The investment will support ongoing clinical studies and development programs.

Has Radiopharm reported any clinical updates?

Yes, Radiopharm has reported positive clinical updates across multiple programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm A$18 million clinical studies therapeutic candidates investment
Last updated: Jun 20, 2024